Successful Isolation of Infectious and High Titer Human Monocyte-Derived HIV-1 from Two Subjects with Discontinued Therapy

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Wang, Tong ^a,c,d   Xu, Younong ^a   Zhu, Haiying ^a   Andrus, Thomas ^a   Ivanov, Sergei B ^a   Pan, Charlotte ^a   Dolores, Jazel ^a   Dann, Gregory C ^a   Zhou, Michael ^a   Forte, Dominic ^a   Yang, Zihuan ^a   Holte, Sarah ^a,b   Corey, Lawrence ^a,b   Zhu, Tuofu ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Key Lab of Reproduction and Genetics of Guangdong Higher Education Institutes   (China)

^d JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; T LYMPHOCYTE RECEPTOR; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA SYNTHESIS; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; VIRUS ISOLATION; VIRUS LOAD; VIRUS RELEASE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; ENZYME ACTIVATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MONOCYTES; PEPTIDE FRAGMENTS; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, CCR5; RECEPTORS, HIV; VIRAL TROPISM; VIRUS REPLICATION;

EQUIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878558258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065071     Document Type: Article

References (87)

1. Muller WA, Randolph GJ, (1999) Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukoc Biol 66: 698-704.
2. Randolph GJ, Sanchez-Schmitz G, Liebman RM, Schakel K, (2002) The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 196: 517-527.
3. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB, (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83: 7089-7093.
4. Ho DD, Rota TR, Hirsch MS, (1986) Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 77: 1712-1715.
5. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, et al. (1990) Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A 87: 6058-6062.
6. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, et al. (1991) Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 164: 1051-1057.
7. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, et al. (1993) Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362.
8. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, et al. (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355-358.
9. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, et al. (1996) Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol 70: 3863-3869.
10. Orenstein JM, Fox C, Wahl SM, (1997) Macrophages as a source of HIV during opportunistic infections. Science 276: 1857-1861.
11. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, et al. (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964.
12. Schrager LK, D'Souza MP, (1998) Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280: 67-71.
13. Cavert W, Haase AT, (1998) A national tissue bank to track HIV eradication and immune reconstruction. Science 280: 1865-1866.
14. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998) Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427-431.
15. Fulcher JA, Hwangbo Y, Zioni R, Nickle D, Lin X, et al. (2004) Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol 78: 7883-7893.
16. Delobel P, Sandres-Saune K, Cazabat M, L'Faqihi FE, Aquilina C, et al. (2005) Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS 19: 1739-1750.
17. Llewellyn N, Zioni R, Zhu H, Andrus T, Xu Y, et al. (2006) Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. J Leukoc Biol 80: 1118-1126.
18. Xu Y, Zhu H, Wilcox CK, van't Wout A, Andrus T, et al. (2008) Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. J Infect Dis 197: 309-318.
19. Zhu T, (2002) HIV-1 in peripheral blood monocytes: an underrated viral source. J Antimicrob Chemother 50: 309-311.
20. Zhu T, Muthui D, Holte S, Nickle D, Feng F, et al. (2002) Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76: 707-716.
21. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, et al. (2009) HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 72: 992-998.
22. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, et al. (2010) The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 87: 589-598.
23. Persidsky Y, (1999) Model systems for studies of leukocyte migration across the blood- brain barrier. J Neurovirol 5: 579-590.
24. Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, et al. (2006) Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107: 4770-4780.
25. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, et al. (2008) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 180: 1854-1865.
26. Gendelman HE, Ding S, Gong N, Liu J, Ramirez SH, et al. (2009) Monocyte chemotactic protein-1 regulates voltage-gated K+ channels and macrophage transmigration. J Neuroimmune Pharmacol 4: 47-59.
27. Westhorpe CL, Zhou J, Webster NL, Kalionis B, Lewin SR, et al. (2009) Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol 85: 1027-1035.
28. Gonzalez-Scarano F, Martin-Garcia J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
29. Ghafouri M, Amini S, Khalili K, Sawaya BE, (2006) HIV-1 associated dementia: symptoms and causes. Retrovirology 3: 28.
30. Aquaro S, Svicher V, Ronga L, Perno CF, Pollicita M, (2008) HIV-1-associated dementia during HAART therapy. Recent Patents CNS Drug Discov 3: 23-33.
31. Marsden MD, Zack JA, (2009) Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63: 7-10.
32. Persidsky Y, Stins M, Way D, Witte MH, Weinand M, et al. (1997) A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 158: 3499-3510.
33. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, et al. (2008) Proteomic modeling for HIV-1 infected microglia-astrocyte crosstalk. PLoS ONE 3: e2507.
34. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, et al. (2008) HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol 3: 173-186.
35. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD, (2008) STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 111: 2062-2072.
36. Kelly J, Beddall MH, Yu D, Iyer SR, Marsh JW, et al. (2008) Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 372: 300-312.
37. Valcour VG, Shiramizu BT, Shikuma CM, (2010) HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol 87: 621-626.
38. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, et al. (2000) Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 23: 114-119.
39. Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, et al. (2001) Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15: 17-22.
40. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
41. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
42. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
43. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
44. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
45. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95: 8869-8873.
46. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
47. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, et al. (1999) HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy [letter]. Lancet 353: 119-120.
48. Zhang ZQ, Schuler T, Cavert W, Notermans DW, Gebhard K, et al. (1999) Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A 96: 5169-5172.
49. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, et al. (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy [see comments]. N Engl J Med 340: 1614-1622.
50. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6: 757-761.
51. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, et al. (2000) Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6: 76-81.
52. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80: 6441-6457.
53. Zhu T, (2000) HIV-1 genotypes in peripheral blood monocytes. J Leukoc Biol 68: 338-344.
54. Crowe S, Zhu T, Muller WA, (2003) The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 74: 635-641.
55. Schacker T, Collier AC, Hughes J, Shea T, Corey L, (1996) Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125: 257-264.
56. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L, (1998) Biological and virologic characteristics of primary HIV infection. Ann Intern Med 128: 613-620.
57. Resch W, Hoffman N, Swanstrom R, (2001) Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62.
58. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, et al. (2003) Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 31: 3850-3855.
59. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
60. Graham SM, Holte S, Kimata JT, Wener MH, Overbaugh J, (2009) A decrease in albumin in early SIV infection is related to viral pathogenicity. AIDS Res Hum Retroviruses 25: 433-440.
61. Zhu T, Corey L, Hwangbo Y, Lee JM, Learn GH, et al. (2003) Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 77: 6108-6116.
62. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, et al. (1997) Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 62: 138-143.
63. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, et al. (1998) Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 178: 413-422.
64. Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, et al. (2001) The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 75: 4402-4406.
65. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, et al. (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 68: 479-488.
66. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16: 446-451.
67. Kadiu I, Narayanasamy P, Dash PK, Zhang W, Gendelman HE, (2012) Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol 189: 744-754.
68. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, et al. (2002) Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res Hum Retroviruses 18: 353-362.
69. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, et al. (2005) Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 337: 384-398.
70. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG, (1998) CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 72: 772-777.
71. Yi Y, Shaheen F, Collman RG, (2005) Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol 79: 1480-1486.
72. Triques K, Stevenson M, (2004) Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol 78: 5523-5527.
73. Arfi V, Riviere L, Jarrosson-Wuilleme L, Goujon C, Rigal D, et al. (2008) Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol 82: 6557-6565.
74. Cywin CL, Klunder JM, Hoermann M, Brickwood JR, David E, et al. (1998) Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones. J Med Chem 41: 2972-2984.
75. Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, et al. (2004) Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. J Clin Virol 31: 198-203.
76. Wind-Rotolo M, Durand C, Cranmer L, Reid A, Martinson N, et al. (2009) Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis 199: 1301-1309.
77. Kagan RM, Sista P, Pattery T, Bacheler L, Schwab DA, (2009) Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 23: 1602-1605.
78. Soulie C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, et al. (2009) Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor+protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor+nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Aids 23: 1605-1608.
79. Polilli E, Di Masi F, Sozio F, Mazzotta E, Alterio L, et al. (2009) Sequential transmission and long-term persistence of an HIV strain partially resistant to protease inhibitors. New Microbiol 32: 205-208.
80. O'Brien WA, Namazi A, Kalhor H, Mao SH, Zack JA, et al. (1994) Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol 68: 1258-1263.
81. Bergamaschi A, Pancino G, (2010) Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7: 31.
82. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, et al. (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110: 393-400.
83. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
84. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
85. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
86. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J, (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777-6780.
87. Deng W, Maust BS, Nickle DC, Learn GH, Liu Y, et al. (2010) DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. BioTechniques 48: 405-408.